Triumph Research Intelligence (TRI)

Triumph Research Intelligence (TRI) offers a specialized Risk-Based Quality Management (RBQM) platform designed to enhance clinical trials by streamlining risk identification and management processes for pharmaceutical companies and CROs. Founded in 2013 by Duncan Hall, Triumph Research Intelligence (TRI) is headquartered in Essex, UK. The company provides advanced solutions for clinical trials and underwent significant growth with its operational model, focusing on risk management in clinical research. The most recent deal took place on October 15, 2018, where TRI raised growth capital funding led by Octopus Investments.

TRI specializes in delivering a comprehensive Risk-Based Quality Management (RBQM) platform for the clinical trials industry. Their main offerings, OPRA Central Monitoring (OPRA-CM) and OPRA Risk Assessment & Management (OPRA-RAM), assist clinical trial sponsors and Contract Research Organizations (CROs) in optimizing risk management processes. These tools promote centralized risk management, enhance automation, and provide dynamic data visualization throughout the trial lifecycle, catering to clients in North America, Europe, and Asia. TRI's revenue model is grounded in subscription services and partnerships, granting clients continuous access to its RBQM solutions.

Clients typically license the OPRA platform for clinical trial use, with fees determined by the scale and scope of their projects. This B2B structure integrates TRI's technology into client operations, ensuring compliance and quality management enhancements. Following the growth capital funding raised in October 2018, TRI plans to develop new features for its OPRA platform and expand into additional markets, particularly targeting regions in Asia and Europe by 2025. The investment will support product innovation and broader market penetration.